ARIMIDEX: A new oral, once-a-day aromatase inhibitor

Paul V. Plourde, Martin Dyroff, Mitch Dowsett, Laurence Demers, Roger Yates, Alan Webster

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

ARIMIDEX® is a potent and selective aromatase inhibitor undergoing evaluation as a treatment for postmenopausal women with advanced breast cancer. Studies examining the pharmacology of ARIMIDEX were conducted in both animals and humans. In animals, ARIMIDEX elicits maximal aromatase suppressive activity at a dose of approx. 0.1 mg/kg, does not alter adrenal steroid hormone biosynthesis, and at a dose of 1 mg/kg, has no other pharmacologic effects other than aromatase inhibition. In this overview, the pharmacodynamic, pharmacokinetic, and safety profiles of single and multiple daily doses of ARIMIDEX are reported in humans. Daily doses of 1-10 mg of ARIMIDEX suppressed estradiol levels to the maximum degree measurable using sensitive estrogen assays. ARIMIDEX had no clinically significant effects on the response of cortisol and aldosterone to ACTH stimulation. Absorption of ARIMIDEX was rapid, with maximum plasma concentrations occurring within 2 h after oral administration. Plasma concentrations of ARIMIDEX rose with increasing doses of the drug. The elimination half-life of ARIMIDEX in humans ranged from 30 to 60 h. Consistent with the long plasma half-life, steady state plasma concentrations were 3-4-fold higher than plasma concentrations observed after single administration of 1, 3, 5, or 10 mg doses. Long term treatment of breast cancer patients with 10 mg/day has continued in 17 patients without an escape of estradiol suppression. Previously, these patients had received on average 2.6 systemic treatments for breast cancer and had significant metastatic disease. Three of the 17 patients continued ARIMIDEX treatment for 20 months and beyond. Given the number of previous treatments and tumor burden at the start of treatment, the response to ARIMIDEX treatment is encouraging. Phase III studies are now underway to assess the efficacy and safety of ARIMIDEX in the treatment of advanced breast cancer.

Original languageEnglish (US)
Pages (from-to)175-179
Number of pages5
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume53
Issue number1-6
DOIs
StatePublished - Jan 1 1995

Fingerprint

Aromatase Inhibitors
Plasmas
Aromatase
Breast Neoplasms
Estradiol
Animals
Steroid hormones
Pharmacodynamics
Therapeutics
Pharmacokinetics
Biosynthesis
Half-Life
Aldosterone
Adrenocorticotropic Hormone
Hydrocortisone
Tumors
Assays
Safety
Estrogens
Tumor Burden

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Endocrinology
  • Clinical Biochemistry
  • Cell Biology

Cite this

Plourde, P. V., Dyroff, M., Dowsett, M., Demers, L., Yates, R., & Webster, A. (1995). ARIMIDEX: A new oral, once-a-day aromatase inhibitor. Journal of Steroid Biochemistry and Molecular Biology, 53(1-6), 175-179. https://doi.org/10.1016/0960-0760(95)00045-2
Plourde, Paul V. ; Dyroff, Martin ; Dowsett, Mitch ; Demers, Laurence ; Yates, Roger ; Webster, Alan. / ARIMIDEX : A new oral, once-a-day aromatase inhibitor. In: Journal of Steroid Biochemistry and Molecular Biology. 1995 ; Vol. 53, No. 1-6. pp. 175-179.
@article{f4c41bdcf4f84557aebd176370608c41,
title = "ARIMIDEX™: A new oral, once-a-day aromatase inhibitor",
abstract = "ARIMIDEX{\circledR} is a potent and selective aromatase inhibitor undergoing evaluation as a treatment for postmenopausal women with advanced breast cancer. Studies examining the pharmacology of ARIMIDEX were conducted in both animals and humans. In animals, ARIMIDEX elicits maximal aromatase suppressive activity at a dose of approx. 0.1 mg/kg, does not alter adrenal steroid hormone biosynthesis, and at a dose of 1 mg/kg, has no other pharmacologic effects other than aromatase inhibition. In this overview, the pharmacodynamic, pharmacokinetic, and safety profiles of single and multiple daily doses of ARIMIDEX are reported in humans. Daily doses of 1-10 mg of ARIMIDEX suppressed estradiol levels to the maximum degree measurable using sensitive estrogen assays. ARIMIDEX had no clinically significant effects on the response of cortisol and aldosterone to ACTH stimulation. Absorption of ARIMIDEX was rapid, with maximum plasma concentrations occurring within 2 h after oral administration. Plasma concentrations of ARIMIDEX rose with increasing doses of the drug. The elimination half-life of ARIMIDEX in humans ranged from 30 to 60 h. Consistent with the long plasma half-life, steady state plasma concentrations were 3-4-fold higher than plasma concentrations observed after single administration of 1, 3, 5, or 10 mg doses. Long term treatment of breast cancer patients with 10 mg/day has continued in 17 patients without an escape of estradiol suppression. Previously, these patients had received on average 2.6 systemic treatments for breast cancer and had significant metastatic disease. Three of the 17 patients continued ARIMIDEX treatment for 20 months and beyond. Given the number of previous treatments and tumor burden at the start of treatment, the response to ARIMIDEX treatment is encouraging. Phase III studies are now underway to assess the efficacy and safety of ARIMIDEX in the treatment of advanced breast cancer.",
author = "Plourde, {Paul V.} and Martin Dyroff and Mitch Dowsett and Laurence Demers and Roger Yates and Alan Webster",
year = "1995",
month = "1",
day = "1",
doi = "10.1016/0960-0760(95)00045-2",
language = "English (US)",
volume = "53",
pages = "175--179",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier Limited",
number = "1-6",

}

Plourde, PV, Dyroff, M, Dowsett, M, Demers, L, Yates, R & Webster, A 1995, 'ARIMIDEX: A new oral, once-a-day aromatase inhibitor', Journal of Steroid Biochemistry and Molecular Biology, vol. 53, no. 1-6, pp. 175-179. https://doi.org/10.1016/0960-0760(95)00045-2

ARIMIDEX : A new oral, once-a-day aromatase inhibitor. / Plourde, Paul V.; Dyroff, Martin; Dowsett, Mitch; Demers, Laurence; Yates, Roger; Webster, Alan.

In: Journal of Steroid Biochemistry and Molecular Biology, Vol. 53, No. 1-6, 01.01.1995, p. 175-179.

Research output: Contribution to journalArticle

TY - JOUR

T1 - ARIMIDEX™

T2 - A new oral, once-a-day aromatase inhibitor

AU - Plourde, Paul V.

AU - Dyroff, Martin

AU - Dowsett, Mitch

AU - Demers, Laurence

AU - Yates, Roger

AU - Webster, Alan

PY - 1995/1/1

Y1 - 1995/1/1

N2 - ARIMIDEX® is a potent and selective aromatase inhibitor undergoing evaluation as a treatment for postmenopausal women with advanced breast cancer. Studies examining the pharmacology of ARIMIDEX were conducted in both animals and humans. In animals, ARIMIDEX elicits maximal aromatase suppressive activity at a dose of approx. 0.1 mg/kg, does not alter adrenal steroid hormone biosynthesis, and at a dose of 1 mg/kg, has no other pharmacologic effects other than aromatase inhibition. In this overview, the pharmacodynamic, pharmacokinetic, and safety profiles of single and multiple daily doses of ARIMIDEX are reported in humans. Daily doses of 1-10 mg of ARIMIDEX suppressed estradiol levels to the maximum degree measurable using sensitive estrogen assays. ARIMIDEX had no clinically significant effects on the response of cortisol and aldosterone to ACTH stimulation. Absorption of ARIMIDEX was rapid, with maximum plasma concentrations occurring within 2 h after oral administration. Plasma concentrations of ARIMIDEX rose with increasing doses of the drug. The elimination half-life of ARIMIDEX in humans ranged from 30 to 60 h. Consistent with the long plasma half-life, steady state plasma concentrations were 3-4-fold higher than plasma concentrations observed after single administration of 1, 3, 5, or 10 mg doses. Long term treatment of breast cancer patients with 10 mg/day has continued in 17 patients without an escape of estradiol suppression. Previously, these patients had received on average 2.6 systemic treatments for breast cancer and had significant metastatic disease. Three of the 17 patients continued ARIMIDEX treatment for 20 months and beyond. Given the number of previous treatments and tumor burden at the start of treatment, the response to ARIMIDEX treatment is encouraging. Phase III studies are now underway to assess the efficacy and safety of ARIMIDEX in the treatment of advanced breast cancer.

AB - ARIMIDEX® is a potent and selective aromatase inhibitor undergoing evaluation as a treatment for postmenopausal women with advanced breast cancer. Studies examining the pharmacology of ARIMIDEX were conducted in both animals and humans. In animals, ARIMIDEX elicits maximal aromatase suppressive activity at a dose of approx. 0.1 mg/kg, does not alter adrenal steroid hormone biosynthesis, and at a dose of 1 mg/kg, has no other pharmacologic effects other than aromatase inhibition. In this overview, the pharmacodynamic, pharmacokinetic, and safety profiles of single and multiple daily doses of ARIMIDEX are reported in humans. Daily doses of 1-10 mg of ARIMIDEX suppressed estradiol levels to the maximum degree measurable using sensitive estrogen assays. ARIMIDEX had no clinically significant effects on the response of cortisol and aldosterone to ACTH stimulation. Absorption of ARIMIDEX was rapid, with maximum plasma concentrations occurring within 2 h after oral administration. Plasma concentrations of ARIMIDEX rose with increasing doses of the drug. The elimination half-life of ARIMIDEX in humans ranged from 30 to 60 h. Consistent with the long plasma half-life, steady state plasma concentrations were 3-4-fold higher than plasma concentrations observed after single administration of 1, 3, 5, or 10 mg doses. Long term treatment of breast cancer patients with 10 mg/day has continued in 17 patients without an escape of estradiol suppression. Previously, these patients had received on average 2.6 systemic treatments for breast cancer and had significant metastatic disease. Three of the 17 patients continued ARIMIDEX treatment for 20 months and beyond. Given the number of previous treatments and tumor burden at the start of treatment, the response to ARIMIDEX treatment is encouraging. Phase III studies are now underway to assess the efficacy and safety of ARIMIDEX in the treatment of advanced breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0028990478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028990478&partnerID=8YFLogxK

U2 - 10.1016/0960-0760(95)00045-2

DO - 10.1016/0960-0760(95)00045-2

M3 - Article

C2 - 7626450

AN - SCOPUS:0028990478

VL - 53

SP - 175

EP - 179

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

IS - 1-6

ER -